Effectiveness of a simply designed tumor vaccine in prevention of malignant melanoma development.
We investigated the efficacy of a simple syngeneic tumor vaccine to induce specific antitumor immunity in female C57Bl/6 mice. Tumor vaccine was prepared by mixing irradiated B-16 melanoma tumor cells with the pleiotropic biological response modifier-maleic anhydride divinyl ether (MVE-2). Experimental animals were pretreated with the vaccine in order to prevent the development of intraperitoneal (i.p.) B-16 melanoma tumors after inoculation of viable tumor cells. More than 40% of prevaccinated animals challenged i.p. with 5 x 10(5) viable tumor cells were completely protected from tumor development and remained tumor-free 100 days after tumor cell inoculation. The percentage of tumor-free animals (survivors) rose to as much as 90% when the application of tumor vaccine was repeated two weeks after the first vaccination (i.e. one week after the inoculation of viable tumor cells). The induced antitumor response depended predominantly upon macrophage function, since vaccinated animals which were depleted of peritoneal macrophages died within the same time range as animals in the control group. Also, tumor-type specificity of the vaccine was confirmed by the fact that the animals vaccinated with B-16 melanoma vaccine were not protected from the development of another type of tumor. In conclusion, comparison of the experimental data with the data from the literature suggests that our simple tumor vaccine may be as effective as genetically engineered tumor vaccines. At the same time, this kind of vaccine is easier to control and thus safer to apply in humans when compared to genetically engineered vaccines.
Novaković
S
S
Department of Tumor Biology, Institute of Oncology, Ljubljana, Slovenia. snovakovic@onko-i.si
Ihan
A
A
Jezersek
B
B
D000818:Animals; D000943:Antigens, Differentiation / Q000032:analysis; D019496:Cancer Vaccines; D004334:Drug Administration Schedule; D005260:Female; D005434:Flow Cytometry; D007155:Immunologic Factors; D018655:Lymphocyte Count; D017737:Macrophages, Peritoneal / Q000276:immunology*; D008546:Melanoma, Experimental / Q000276:immunology* / Q000517:prevention & control*; D051379:Mice; D008810:Mice, Inbred C57BL; D011713:Pyran Copolymer; D013997:Time Factors; D014407:Tumor Cells, Cultured
D000943:Antigens, Differentiation; D019496:Cancer Vaccines; D007155:Immunologic Factors; D011713:Pyran Copolymer